AMAG Names New Vice President, Chief Commercial Officer

LEXINGTON, Mass.—AMAG Pharmaceuticals Inc. announced April 27 the appointment of Gary J. Zieziula as executive vice president and chief commercial officer.
 
In this newly created position, Zieziula will be responsible for the company's commercial organization including sales, managed markets and reimbursement, marketing, market research, commercial analytics, and sales operations.
 
He will lead the company's global commercial strategy in support of the planned label expansion for Feraheme) Injection for intravenous (IV) use across all therapeutic indications and imaging applications and evaluate the commercial attractiveness of potential in-licensing opportunities.
 
Zieziula has more than 25 years of pharmaceutical experience, most recently serving as the managing director, pharmaceuticals for Roche (Hellas) S.A. in Greece. Since joining Roche in 2001, he has held several key sales and marketing positions, including head of commercial operations, specialty care at Roche USA, where he was responsible for oncology, transplant, anti-infectives and antivirals/HIV products, which together had total annual revenues exceeding $2.5 billion during. Zieziula's tenure.
 
"Gary's global experience in commercializing a broad range of therapeutic products will serve AMAG well as we look to expand the label for Feraheme," said Brian J. G. Pereira, M.D., president and CEO of AMAG Pharmaceuticals. "The addition of Gary further strengthens our management team as we seek to unlock the value of Feraheme for patients with iron deficiency anemia with or without chronic kidney disease around the world, as well as the potential of ferumoxytol as an imaging agent."